JP2002020320A - Antiseptic agent for eye drop - Google Patents
Antiseptic agent for eye dropInfo
- Publication number
- JP2002020320A JP2002020320A JP2000198032A JP2000198032A JP2002020320A JP 2002020320 A JP2002020320 A JP 2002020320A JP 2000198032 A JP2000198032 A JP 2000198032A JP 2000198032 A JP2000198032 A JP 2000198032A JP 2002020320 A JP2002020320 A JP 2002020320A
- Authority
- JP
- Japan
- Prior art keywords
- preservative
- ophthalmic solution
- polymer
- basic amino
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、点眼液用防腐剤お
よび点眼液に関する。TECHNICAL FIELD The present invention relates to a preservative for eye drops and an eye drop.
【０００２】[0002]
【従来の技術】点眼液は、眼という人体の鋭敏な器官に
直接投与されるため、その配合成分の選択には特に注意
を要する。点眼液に使用される防腐剤は、食品、ドリン
ク剤、コンタクトレンズ保存液等に用いられる防腐剤
（保存剤）と同列に扱うことはできず、例えば、眼刺激
性、生じ得る様々な副作用、さらに長期保存を可能にす
るためには点眼液の経時安定性にも配慮されなければな
らない。2. Description of the Related Art Eye drops are administered directly to the sensitive organs of the human body, which is the eye. Preservatives used in eye drops cannot be treated in the same manner as preservatives (preservatives) used in foods, drinks, contact lens preservatives, etc., for example, eye irritation, various side effects that may occur, Furthermore, in order to enable long-term storage, the temporal stability of the ophthalmic solution must be considered.
【０００３】従来より、点眼液の防腐剤として、塩化ベ
ンザルコニウム、塩化ベンゼトニウム、ソルビン酸等が
用いられている。Conventionally, benzalkonium chloride, benzethonium chloride, sorbic acid and the like have been used as preservatives for eye drops.
【０００４】しかし、塩化ベンザルコニウムや塩化ベン
ゼトニウムは、防腐効果は高いもののその濃度が高くな
れば角膜障害を引き起こすことがあるので、その使用濃
度には一定の制約を伴う。また、これらの防腐剤は、酸
性の添加物と配合変化（化学反応）を起こすことがあ
り、ろ過フィルターや点眼容器に吸着されやすい性質も
ある。他方、ソルビン酸は、点眼容器への吸着は少ない
ものの、防腐効果が顕著でなく、また、pHによっては安
定性が低下し、眼刺激性を生じることもあるので、同時
に配合できる薬物や他の添加物には一定の制約がある。[0004] However, benzalkonium chloride and benzethonium chloride have a high preservative effect, but may cause corneal damage if the concentration thereof is high, so that there is a certain restriction on the use concentration. In addition, these preservatives may cause a mixing change (chemical reaction) with an acidic additive, and have a property of being easily adsorbed to a filter or an ophthalmic container. On the other hand, sorbic acid has low adsorption to eye drops, but does not have a remarkable preservative effect.In addition, depending on pH, stability may be reduced and eye irritation may occur. Additives have certain restrictions.
【０００５】[0005]
【発明が解決しようとする課題】そこで、点眼液におい
て、防腐効果に優れ、同時に配合できる薬物や他の添加
物に制約されることが少なく、かつ、安全性にも優れた
な点眼液用防腐剤が求められている。Therefore, an ophthalmic preservative for an ophthalmic solution which has an excellent preservative effect, is hardly restricted by drugs and other additives which can be incorporated at the same time, and is also excellent in safety. Agents are needed.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、かかる課
題を解決できる点眼液用防腐剤を探索したところ、点眼
液において塩基性アミノ酸のポリマーが優れた防腐効果
を発揮し、また、塩基性アミノ酸のポリマーとホウ酸お
よび／またはホウ砂を併用すれば、点眼液における防腐
効果がより増強されることを見出し本発明に至った。Means for Solving the Problems The present inventors have searched for an ophthalmic solution preservative which can solve the above problems, and found that a polymer of a basic amino acid exhibits an excellent antiseptic effect in ophthalmic solution, It has been found that the preservative effect of the ophthalmic solution can be further enhanced by using a polymer of a sex amino acid and boric acid and / or borax in combination, and has reached the present invention.
【０００７】すなわち、本発明は、塩基性アミノ酸のポ
リマーからなる防腐効果に優れた点眼液用防腐剤および
点眼液に関するものである。さらに、塩基性アミノ酸の
ポリマーとホウ酸および／またはホウ砂からなる防腐効
果に優れた点眼液用防腐剤および点眼液に関する。That is, the present invention relates to a preservative for eye drops and an eye drop comprising a polymer of a basic amino acid and having an excellent preservative effect. Further, the present invention relates to a preservative for eye drops and an eye drop comprising a polymer of a basic amino acid and boric acid and / or borax, which have excellent preservative effects.
【０００８】[0008]
【発明の実施の形態】本発明の点眼液用防腐剤は、塩基
性アミノ酸のポリマーからなる。塩基性アミノ酸のポリ
マーとしては、例えばポリリジン、ポリオルニチン、ポ
リアルギニン、ポリヒスチジン等が挙げられ、これらの
いずれかを単独で使用してもよく、また、２種以上を組
み合わせて使用することもできる。これらの塩基性アミ
ノ酸のポリマーは、点眼後眼部組織に吸収されず生体内
のタンパク分解酵素により生体内成分であるアミノ酸に
容易に分解されるため、人体に対する安全性に極めて優
れている。塩基性アミノ酸のポリマーの添加量は特に制
限されないが、０．００００１〜５．０重量％の範囲
で、より好ましくは０．０００１〜３．０重量％の範囲
である。塩基性アミノ酸のポリマーの点眼液における添
加量が０．００００１重量％未満であれば点眼液におい
て充分な防腐効果が得られず、また、５．０重量％を超
えても防腐効果はほとんど向上しないからである。BEST MODE FOR CARRYING OUT THE INVENTION The preservative for eye drops of the present invention comprises a polymer of a basic amino acid. Examples of the polymer of a basic amino acid include polylysine, polyornithine, polyarginine, polyhistidine, and the like. Any of these may be used alone, or two or more may be used in combination. . Polymers of these basic amino acids are not absorbed by the ocular tissues after instillation and are easily decomposed into amino acids, which are components in the living body, by proteolytic enzymes in the living body. The amount of the basic amino acid polymer to be added is not particularly limited, but is in the range of 0.00001 to 5.0% by weight, and more preferably in the range of 0.0001 to 3.0% by weight. If the amount of the basic amino acid polymer added to the ophthalmic solution is less than 0.00001% by weight, a sufficient antiseptic effect cannot be obtained in the ophthalmic solution, and if it exceeds 5.0% by weight, the antiseptic effect is hardly improved. Because.
【０００９】塩基性アミノ酸のポリマーの重量平均分子
量は特に制限されないが、５００〜５０００００の範囲
で、より好ましくは３０００〜２０００００の範囲であ
る。重量平均分子量が５００未満では点眼液において充
分な防腐効果が得られず、また、５０００００を超える
と点眼液が粘稠となりすぎ、不快な粘つき感を伴うこと
があるからである。The weight average molecular weight of the polymer of the basic amino acid is not particularly limited, but is in the range of 500 to 500,000, more preferably 3000 to 200,000. If the weight average molecular weight is less than 500, a sufficient preservative effect cannot be obtained in the ophthalmic solution, and if it exceeds 500,000, the ophthalmic solution becomes too viscous and may have an unpleasant sticky feeling.
【００１０】本発明の点眼液用防腐剤にホウ酸および／
またはホウ砂を添加すれば、点眼液の防腐効果がさらに
増強される。点眼液におけるホウ酸および／またはホウ
砂の添加量は特に制限されないが、０．００１〜５．０
重量％の範囲が好ましく、０．０１〜２．０重量％の範
囲がより好ましい。眼に対する安全性を考慮すれば、ホ
ウ酸および／またはホウ砂の添加量は５．０重量％を超
えないことが望ましい。The preservative for ophthalmic solution of the present invention comprises boric acid and / or boric acid.
Alternatively, if borax is added, the preservative effect of the ophthalmic solution is further enhanced. The amount of boric acid and / or borax added in the ophthalmic solution is not particularly limited, but is 0.001 to 5.0.
% By weight, more preferably from 0.01 to 2.0% by weight. In consideration of eye safety, it is desirable that the amount of boric acid and / or borax not exceed 5.0% by weight.
【００１１】本発明の点眼液用防腐剤を含有する点眼液
には、上記防腐剤以外に有効成分である薬物は無論、他
の添加物として、等張化剤、緩衝剤、pH調節剤、可溶化
剤、増粘剤、安定化剤、保存剤等を適宜配合することが
できる。塩基性アミノ酸のポリマーは、他の配合成分
（薬物、添加物等）との相互作用が少なく、同時に配合
する薬物、他の添加物等について制約されることも少な
い。The ophthalmic solution containing the preservative for ophthalmic solution of the present invention contains, as an additive, other than the above-mentioned preservative, of course, a drug as an active ingredient, as an isotonic agent, a buffer, a pH adjuster, A solubilizer, a thickener, a stabilizer, a preservative, and the like can be appropriately blended. The polymer of a basic amino acid has little interaction with other compounding components (drugs, additives, and the like), and there is little restriction on drugs, other additives, and the like to be compounded at the same time.
【００１２】したがって、本発明の点眼液用防腐剤と配
合する薬物は、特に制限されないが、例えば抗緑内障剤
（チモロール、プロスタグランジン誘導体、炭酸脱水酵
素阻害剤等）、各種のビタミン類（ビタミンB2、ビタミ
ンB6、ビタミンB12、ビタミンE、パンテノール等）、充
血除去剤（塩酸テトラヒドロゾリン、塩酸ナファゾリン
等）、抗炎症剤（ジクロフェナク、インドメタシン、フ
ルオロメトロン、プラノプロフェン、グリチルリチン酸
二カリウム、ε-アミノカプロン酸等）、抗ヒスタミン
剤（マレイン酸クロルフェニラミン、塩酸ジフェンヒド
ラミン等）、抗アレルギー剤（クロモグリク酸ナトリウ
ム等）、抗菌剤（キノロン系抗菌剤、セファロスポリン
類、スルファセタミドナトリウム、スルファメトキサゾ
ール等）、アミノ酸類（Ｌ−アスパラギン酸カリウム、
アミノエチルスルホン酸、コンドロイチン硫酸ナトリウ
ム等）、診断用試薬（ナトリウムフルオレセイン等）、
ヒアルロン酸ナトリウム、メチル硫酸ネオスチグミン等
を挙げることができる。Accordingly, the drug to be combined with the preservative for ophthalmic solution of the present invention is not particularly limited. For example, anti-glaucoma (timolol, prostaglandin derivative, carbonic anhydrase inhibitor, etc.), various vitamins (vitamin B2, vitamin B6, vitamin B12, vitamin E, panthenol, etc., decongestants (tetrahydrozoline hydrochloride, naphazoline hydrochloride, etc.), anti-inflammatory agents (diclofenac, indomethacin, fluorometholone, planoprofen, dipotassium glycyrrhizinate, ε- Aminocaproic acid, etc.), antihistamines (chlorpheniramine maleate, diphenhydramine hydrochloride, etc.), antiallergic agents (sodium cromoglycate, etc.), antibacterial agents (quinolone antibacterial agents, cephalosporins, sodium sulfacetamide, sulfamethoki) Sazol), amino acids Potassium L- aspartic acid,
Aminoethylsulfonic acid, sodium chondroitin sulfate, etc.), diagnostic reagents (sodium fluorescein, etc.),
Examples include sodium hyaluronate and neostigmine methyl sulfate.
【００１３】等張化剤としては、例えばグリセリン、プ
ロピレングリコール、塩化ナトリウム、塩化カリウム、
ソルビトール、マンニトール等を挙げることができる。Examples of the tonicity agent include glycerin, propylene glycol, sodium chloride, potassium chloride,
Sorbitol, mannitol and the like can be mentioned.
【００１４】緩衝剤としては例えば、リン酸、リン酸
塩、クエン酸、酢酸、ε-アミノカプロン酸、トロメタ
モール等を挙げることができる。Examples of the buffer include phosphoric acid, phosphate, citric acid, acetic acid, ε-aminocaproic acid, tromethamol and the like.
【００１５】pH調節剤としては、例えば塩酸、クエン
酸、リン酸、酢酸、水酸化ナトリウム、水酸化カリウ
ム、炭酸ナトリウム、炭酸水素ナトリウム等を挙げるこ
とができる。Examples of the pH adjuster include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like.
【００１６】薬物や他の添加物が水難溶性の場合等に添
加される可溶化剤としては、例えばポリソルベート８
０、ポリオキシエチレン硬化ヒマシ油６０、マクロゴー
ル４０００等を挙げることができる。As a solubilizer to be added when a drug or other additives are hardly soluble in water, for example, polysorbate 8
0, polyoxyethylene hydrogenated castor oil 60, Macrogol 4000 and the like.
【００１７】増粘剤としては、例えばヒドロキシプロピ
ルメチルセルロース、ヒドロキシプロピルセルロース等
のセルロース系高分子、ポリビニルアルコール、ポリビ
ニルピロリドン等を、また、安定化剤としては、例えば
エデト酸、エデト酸ナトリウム等を挙げることができ
る。Examples of the thickener include cellulosic polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyvinyl alcohol and polyvinylpyrrolidone, and examples of the stabilizer include edetic acid and sodium edetate. be able to.
【００１８】本発明の点眼液用防腐剤以外の保存剤（防
腐剤）としては、汎用のソルビン酸、ソルビン酸カリウ
ム、塩化ベンザルコニウム、塩化ベンゼトニウム、パラ
オキシ安息香酸メチル、パラオキシ安息香酸プロピル、
クロロブタノール等が挙げられ、本発明の点眼液用防腐
剤はこれらの保存剤を組み合わせて使用することもでき
る。これらの保存剤を併用すれば、汎用の保存剤の使用
量を大幅に減少でき、人体に対する安全性もより向上す
る。Examples of preservatives (preservatives) other than the preservatives for ophthalmic solutions of the present invention include general-purpose sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl parahydroxybenzoate, propyl paraoxybenzoate,
Chlorobutanol and the like can be mentioned, and the preservative for eye drops of the present invention can be used in combination with these preservatives. When these preservatives are used in combination, the amount of general-purpose preservatives can be significantly reduced, and the safety for the human body is further improved.
【００１９】本発明の点眼液用防腐剤を含有する点眼液
は、ｐＨは４．０〜８．０に設定することが望ましく、
浸透圧比は１．０付近に設定することが望ましい。The pH of the ophthalmic solution containing the preservative for ophthalmic solution of the present invention is preferably set to 4.0 to 8.0.
The osmotic pressure ratio is desirably set to around 1.0.
【００２０】本発明の点眼液用防腐剤を含有する点眼液
は、ポリリジン、ポリオルニチン、ポリアルギニン、ポ
リヒスチジン等の塩基性アミノ酸のポリマーを含んでい
るので、細菌や真菌等の各種の菌に対して顕著な抗菌作
用を呈し、安定性にも優れ、人体に対する安全性が極め
て高く、さらに、眼刺激性が少なく差し心地も優れてい
る。Since the ophthalmic solution containing the preservative for ophthalmic solution of the present invention contains a polymer of a basic amino acid such as polylysine, polyornithine, polyarginine, polyhistidine, it can be used for various bacteria such as bacteria and fungi. On the other hand, it has a remarkable antibacterial effect, is excellent in stability, is extremely safe for the human body, and has little eye irritation and is excellent in comfort.
【００２１】以下に、実施例を挙げて本発明を詳しく説
明するが、これらは本発明の範囲を限定するものではな
い。Hereinafter, the present invention will be described in detail with reference to examples, but these do not limit the scope of the present invention.
【００２２】[0022]
【実施例】本発明の点眼液用防腐剤を含有する点眼液の
防腐効果を調べるため、以下に示す保存効力試験を行っ
た。EXAMPLES In order to examine the preservative effect of the ophthalmic solution containing the preservative for ophthalmic solution of the present invention, the following preservative efficacy test was carried out.
【００２３】１．Ｅ.coliに対する保存効力試験 表１の実施例１〜１２に示す配合成分の点眼液を、常法
により調製した。また、各点眼液には等張化剤として塩
化ナトリウムを添加し、浸透圧を１．０に調整し、さら
に、緩衝剤としてリン酸２水素ナトリウムを添加し、必
要に応じて水酸化ナトリウムを加えてｐＨを６．０に調
整した（なお、ホウ酸添加群についてはホウ酸自体に緩
衝作用があるため、緩衝剤を添加しない）。保存効力試
験は、第十三改正日本薬局方の保存効力試験法に準拠し
て行った。試験菌としてEscharichia Coli(Ｅ.coli)を
用いて、６時間後および１４日後の生菌数を測定し、下
記の計算式に従い菌の生存率を算出した。試験結果を表
１に示す。1. Preservation efficacy test for E. coli Ophthalmic solutions having the components shown in Examples 1 to 12 in Table 1 were prepared by a conventional method. Further, to each ophthalmic solution, sodium chloride was added as an isotonic agent, the osmotic pressure was adjusted to 1.0, and sodium dihydrogen phosphate was further added as a buffering agent. In addition, the pH was adjusted to 6.0 (in the boric acid added group, boric acid itself has a buffering action, so no buffer was added). The preservative efficacy test was performed in accordance with the preservative efficacy test method of the 13th revised Japanese Pharmacopoeia. Using Escharichia Coli (E. coli) as a test bacterium, the number of viable bacteria after 6 hours and 14 days was measured, and the survival rate of the bacterium was calculated according to the following formula. Table 1 shows the test results.
【００２４】生存率(％)=６時間後または１４日後の生
菌数／初期菌数×１００Survival rate (%) = viable cell count after 6 hours or 14 days / initial cell count × 100
【００２５】[0025]
【表１】 ２．Ａ.nigerに対する保存効力試験 表２の実施例１３〜１８に示す配合成分の点眼液を、常
法により調製した。また、各点眼液には等張化剤として
塩化ナトリウムを添加し、浸透圧を１．０に調整し、さ
らに、必要に応じて水酸化ナトリウムを加えてｐＨを
６．０に調整した。保存効力試験は、第十三改正日本薬
局方の保存効力試験法に準拠して行った。試験菌とし
て、Aspergillus niger(Ａ.niger)を用いて７日後の生
菌数を測定し、下記の計算式に従い菌の生存率を算出し
た。試験結果を表２に示す。[Table 1] 2. A. Niger Preservation Efficacy Test Ophthalmic solutions of the components shown in Examples 13 to 18 in Table 2 were prepared by a conventional method. Further, sodium chloride was added to each ophthalmic solution as an isotonic agent, the osmotic pressure was adjusted to 1.0, and if necessary, sodium hydroxide was added to adjust the pH to 6.0. The preservative efficacy test was performed in accordance with the preservative efficacy test method of the 13th revised Japanese Pharmacopoeia. The number of viable cells after 7 days was measured using Aspergillus niger (A. niger) as a test bacterium, and the survival rate of the bacterium was calculated according to the following formula. Table 2 shows the test results.
【００２６】 生存率(％)=７日後の生菌数／初期菌数×１００Survival rate (%) = viable cell count after 7 days / initial cell count × 100
【００２７】[0027]
【表２】 [Table 2]
【００２８】[0028]
【発明の効果】表１の結果から明らかなように、ポリリ
ジン、ポリオルニチンおよびポリアルギニンはいずれ
も、細菌であるEscharichia Coliに対して優れた防腐
効果を発揮する。また、これらの塩基性アミノ酸のポリ
マーとホウ酸を併用すれば、防腐効果が顕著に増加す
る。表２の結果から明らかなように、ポリリジン、ポリ
オルニチンまたはポリアルギニンとホウ酸を併用すれ
ば、真菌であるAspergillus nigerに対して優れた防腐
効果を発揮する。このように、本発明の点眼液用防腐剤
を含有する点眼液は、その成分として塩基性アミノ酸の
ポリマーを含んでいるので、細菌、真菌等の各種の菌に
対して顕著な抗菌作用を呈する。As is evident from the results in Table 1, all of polylysine, polyornithine and polyarginine exhibit an excellent preservative effect against bacteria Escharichia Coli. In addition, when a polymer of these basic amino acids and boric acid are used in combination, the preservative effect is significantly increased. As is clear from the results in Table 2, when polylysine, polyornithine or polyarginine is used in combination with boric acid, an excellent antiseptic effect is exerted on the fungus Aspergillus niger. As described above, since the ophthalmic solution containing the preservative for ophthalmic solution of the present invention contains a polymer of a basic amino acid as a component thereof, it exhibits a remarkable antibacterial action against various bacteria such as bacteria and fungi. .
Claims (7)
用防腐剤。An antiseptic for ophthalmic solution comprising a polymer of a basic amino acid.
／またはホウ砂からなる点眼液用防腐剤。2. An ophthalmic preservative comprising a polymer of a basic amino acid and boric acid and / or borax.
ポリオルニチン、ポリアルギニンおよびポリヒスチジン
からなる群から選ばれる少なくとも１種を含有する請求
項１または請求項２記載の点眼液用防腐剤。3. The polymer of a basic amino acid is polylysine,
3. The preservative for ophthalmic solution according to claim 1, wherein the preservative comprises at least one selected from the group consisting of polyornithine, polyarginine and polyhistidine.
する点眼液。4. An ophthalmic solution containing the preservative for ophthalmic solution according to claim 1.
れる点眼液用防腐剤。5. An ophthalmic preservative obtained by blending a polymer of a basic amino acid.
／またはホウ砂を配合して得られる点眼液用防腐剤。6. An ophthalmic preservative obtained by blending a polymer of a basic amino acid with boric acid and / or borax.
剤を含有する点眼液。7. An ophthalmic solution containing the preservative for ophthalmic solution according to claim 5 or 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000198032A JP2002020320A (en) | 2000-06-30 | 2000-06-30 | Antiseptic agent for eye drop |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000198032A JP2002020320A (en) | 2000-06-30 | 2000-06-30 | Antiseptic agent for eye drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002020320A true JP2002020320A (en) | 2002-01-23 |
Family
ID=18696255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000198032A Withdrawn JP2002020320A (en) | 2000-06-30 | 2000-06-30 | Antiseptic agent for eye drop |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002020320A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004052403A1 (en) * | 2002-12-11 | 2004-06-24 | Santen Pharmaceutical Co., Ltd. | Preservative for ophthalmology |
| EP1502949A1 (en) * | 2002-04-25 | 2005-02-02 | Toagosei Co., Ltd. | Antimicrobial polypeptide and utizliation thereof |
| JP2005330276A (en) * | 2004-04-23 | 2005-12-02 | Rohto Pharmaceut Co Ltd | Antiseptic and water-based composition containing the same |
| JP2008509980A (en) * | 2004-08-18 | 2008-04-03 | ノバビオティクス・リミテッド | peptide |
| JP2013227343A (en) * | 2004-04-23 | 2013-11-07 | Rohto Pharmaceutical Co Ltd | Antiseptic and aqueous composition containing the same |
| CN104642325A (en) * | 2015-02-04 | 2015-05-27 | 苏州康华净化系统工程有限公司 | Environment-friendly sterilizing agent and preparation method thereof |
| WO2015193677A1 (en) * | 2014-06-20 | 2015-12-23 | Coopervision International Holding Company, Lp | Ophthalmic composition for the treatment of ocular infection |
| CN111840225A (en) * | 2020-08-12 | 2020-10-30 | 王信 | Eye drop for treating glaucoma and preparation method thereof |
-
2000
- 2000-06-30 JP JP2000198032A patent/JP2002020320A/en not_active Withdrawn
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1502949A1 (en) * | 2002-04-25 | 2005-02-02 | Toagosei Co., Ltd. | Antimicrobial polypeptide and utizliation thereof |
| EP1502949B1 (en) * | 2002-04-25 | 2010-11-24 | Toagosei Co., Ltd. | Antimicrobial polypeptide and utilization thereof |
| WO2004052403A1 (en) * | 2002-12-11 | 2004-06-24 | Santen Pharmaceutical Co., Ltd. | Preservative for ophthalmology |
| JP2005330276A (en) * | 2004-04-23 | 2005-12-02 | Rohto Pharmaceut Co Ltd | Antiseptic and water-based composition containing the same |
| JP2013227343A (en) * | 2004-04-23 | 2013-11-07 | Rohto Pharmaceutical Co Ltd | Antiseptic and aqueous composition containing the same |
| JP2008509980A (en) * | 2004-08-18 | 2008-04-03 | ノバビオティクス・リミテッド | peptide |
| GB2541840A (en) * | 2014-06-20 | 2017-03-01 | Coopervision Int Holding Co Lp | Ophthalmic composition for the treatment of ocular infection |
| WO2015193677A1 (en) * | 2014-06-20 | 2015-12-23 | Coopervision International Holding Company, Lp | Ophthalmic composition for the treatment of ocular infection |
| AU2015275896A1 (en) * | 2014-06-20 | 2017-01-12 | Coopervision International Limited | Ophthalmic composition for the treatment of ocular infection |
| AU2015275896B2 (en) * | 2014-06-20 | 2017-05-18 | Coopervision International Limited | Ophthalmic composition for the treatment of ocular infection |
| GB2541840B (en) * | 2014-06-20 | 2017-09-06 | Coopervision Int Holding Co Lp | Ophthalmic composition for the treatment of ocular infection |
| US9789058B2 (en) | 2014-06-20 | 2017-10-17 | Coopervision International Holding Company, Lp | Ophthalmic composition for the treatment of ocular infection |
| CN104642325A (en) * | 2015-02-04 | 2015-05-27 | 苏州康华净化系统工程有限公司 | Environment-friendly sterilizing agent and preparation method thereof |
| CN111840225A (en) * | 2020-08-12 | 2020-10-30 | 王信 | Eye drop for treating glaucoma and preparation method thereof |
| CN111840225B (en) * | 2020-08-12 | 2021-09-14 | 陈丽娜 | Eye drop for treating glaucoma and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6130741B2 (en) | Ophthalmic composition for soft contact lenses | |
| JP5549669B2 (en) | Ophthalmic composition, dry eye treatment and method for stabilizing vitamin A | |
| KR101421519B1 (en) | Self-preserved aqueous pharmaceutical compositions | |
| JP2009173638A (en) | Method of stabilizing ophthalmic composition and vitamin a family | |
| JP2018203791A (en) | Ophthalmologic allergy prophylactic | |
| JP5800072B2 (en) | Ophthalmic composition and method for suppressing cloudiness / precipitation | |
| JP4905616B2 (en) | Eye drops for soft contact lenses | |
| JP2002020320A (en) | Antiseptic agent for eye drop | |
| JP4325129B2 (en) | Preservative | |
| JP2003002837A (en) | Composition for aqueous skin care preparation and method for preventing clouding of liquid composition | |
| JP4801300B2 (en) | Liquid composition for external use | |
| JP5013735B2 (en) | Ocular mucosa application | |
| JP5246182B2 (en) | Eye drops, preservatives and preservatives | |
| US20100021561A1 (en) | Self-preserved aqueous pharmaceutical compositions | |
| CA2413088C (en) | Preservative | |
| JP4524538B2 (en) | Ophthalmic composition | |
| JP5713034B2 (en) | Ophthalmic composition and antiseptic composition for ophthalmic preparation | |
| JP4157988B2 (en) | Water-soluble preparations with no contraindications | |
| EP2419081B1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| JP2005187354A (en) | Aqueous external preparation composition | |
| JP2004203867A (en) | Preservative for ophthalmology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20070904 |